Currently Viewing:
American Society of Clinical Oncology (ASCO) 2017
Dr Barbara McAneny on How the COME HOME Model Helps Cut Hospitalization Rates
June 14, 2017
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13, 2017
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
June 06, 2017
Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model
June 05, 2017
Currently Reading
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 05, 2017
Dr Craig Portell Highlights New and Exciting Treatments for Non-Hodgkin's Lymphoma
June 05, 2017
Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology
June 04, 2017
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 04, 2017
Do We Have Adequate Surveillance in Cancer Survivor Care?
June 04, 2017
Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success
June 04, 2017
Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization
June 03, 2017
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
June 03, 2017
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
June 03, 2017
Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers
June 03, 2017
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
June 01, 2017
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
May 31, 2017

Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk

Surabhi Dangi-Garimella, PhD
Updated results from the POLLUX and CASTOR trials, presented at the 2017 American Society of Clinical Oncology Annual Meeting, have found that including daratumumab in standard-of-care regimens prolonged progression-free survival (PFS) and improved the depth of response, independent of the patientsí cytogenetic risk.
In August 2016, daratumumab (Darzalex), was granted breakthrough designation as second-line treatment for use in combination with either lenalidomide (Revlimid) and dexamethasone (DRd regimen, POLLUX trial) or bortezomib (Velcade) and dexamethasone (DVd regimen, CASTOR trial) for patients with relapsed, refractory multiple myeloma (RRMM) who have received at least 1 prior therapy. Now, updated trial results, presented at the 2017 American Society of Clinical Oncology Annual Meeting, have found that the combination regimens in both trials prolonged progression-free survival (PFS) and improved the depth of response, independent of the patients’ cytogenetic risk.

Daratumumab is a human monoclonal antibody that targets CD38, a cell-surface receptor overexpressed in multiple myeloma, resulting in complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis. Knowing the efficacy of the DRd and DVd regimens, the authors examined their efficacy among RRMM patients with standard or high cytogenetic risk status.

Bone marrow aspirates for patients who participated in the open-label, multicenter, active-controlled, randomized POLLUX and CASTOR studies were collected at screening and assessed centrally via next generation sequencing (NGS). Patients with high-risk cytogenetics included those who had at least 1 of the following translocations or deletions: t(4;14), t(14;16), or del17p. Patients at standard risk were defined as those confirmed negative for these abnormalities. The trial evaluated progression-free survival (PFS) and overall response rate (ORR).

Three-hundred and eleven patient samples were analyzed via NGS from the POLLUX trial and 353 from the CASTOR trial. At a median follow-up of 25.4 months, 65% of patients receiving DRd in the intention-to-treat (ITT) population in the POLLUX trial had a median PFS of 24 months compared with 41% of the control Rd population who had a median PFS of 17.5 months (Hazard ratio [HR], 0.41; 95% CI, 0.31 to 0.53; P<.0001). Among patients who had received 1 prior line of therapy, the median PFS was not reached in 79% of the cohort receiving DRd, compared with 19.6 months PFS in 40% of those treated with Rd (HR, 0.39; 95% CI, 0.26 to 0.58; P<.0001).

At the end of a 19.4-month follow-up period for the CASTOR trial, 49% of patients receiving DVd had a median PFS of 18.7 months, compared with 8% patients treated with Vd who had a median PFS of 7.1 months (HR, 0.31; 95% CI, 0.24 to 0.39; P<.0001). For patients who had received 1 prior line of therapy, median PFS was not reached in 60% of patients in the DVd arm, compared with a median PFS of 7.9 months in 12% of patients in the Vd arm (HR, 0.19; 95% CI, 0.12 to 0.29; P<.0001).

Cytogenetic risk analysis in patients enrolled in the POLLUX study showed that DRd improved median PFS to 22.6 months in the high-risk patient population, compared with 18.2 months in the Rd arm (HR, 0.53; 95% CI, 0.25 to 1.13; P =.0021). Median PFS was not reached in the standard risk patients treated with DRd, compared with PFS of 18.5 months in those receiving Rd (HR, 0.30; 95% CI, 0.20 to 0.47; P<.0001).

Similarly, the median PFS for high-risk patients in the CASTOR study was 11.2 months in the DVd arm, compared with 7.2 months in the Vd arm (HR, 0.45; 95% CI, 0.25 to 0.80; P =.0053). In the standard risk patients, including daratumumab improved median PFS to 19.6 months, compared with 7.9 months with Vd (HR, 0.26; 95% CI, 0.18 to 0.37; P<.0001).

Based on their results, the authors concluded that daratumumab included in standard-of-care regimens in RRMM prolongs PFS and improves the depth of response regardless of cytogenetic risk. Longer-term survival results are awaited for both trials.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!